Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details related to a deferred bonus plan.
Share price data referenced in the transaction includes:
- Ordinary Share price: 1379.00 pence
- American Depositary Share (ADS) price: $42.11
Material Changes
The filing reports increases in the notional interests of specific Directors and PDMRs in GSK Ordinary Shares and ADSs. These increases resulted from the re-investment of dividends paid on shares held in the GlaxoSmithKline 2009 Deferred Annual Bonus Plan. No material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the disclosure of specific share transactions.
Important Facts for Investors
- Transaction Type: Share acquisitions were made via dividend re-investment under the 2009 Deferred Annual Bonus Plan.
- Participants: Transactions involved multiple Directors and PDMRs, including Sir Andrew Witty, Dr. M M Slaoui, and others.
- Acquisition Structure: Acquisitions were split equally between the personal contribution element and the matching element (GSK contribution) for each participant.
- Reporting Date: The Company was advised of these changes on January 12, 2015.